Use of light and turmeric for the treatment of inflammation and mouth sores in cancer patients

Clinical study in cancer patients on the effectiveness of curcumin-mediated photodynamic therapy (APDT) and low-level laser therapy (photobiomodulation) as an adjunct in the treatment of oral mucositis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-9k25ctr

Enrollment

Registered

2026-04-20

Start date

2023-07-14

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candidiasis Oral Stomatitis

Interventions

This is a six-arm, randomized controlled clinical trial where sixty oncology patients with head and neck cancer will be randomly assigned, via sealed envelopes, to groups of ten participants for each

group two will consist of ten patients receiving photobiomodulation with a 660-nanometer laser

group three will consist of ten patients receiving photobiomodulation with a 660-nanometer LED

group four will consist of ten patients receiving laser photobiomodulation combined with curcumin-mediated antimicrobial photodynamic therapy activated by a 450-nanometer blue LED

group five will consist of ten patients receiving laser photobiomodulation combined with treatment for xerostomia

and group six will consist of ten patients receiving laser photobiomodulation combined with curcumin-mediated antimicrobial photodynamic therapy and treatment for xerostomia. Treatments will take plac

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of both sexes and genders aged 18 years or older; patients with stable lesions undergoing chemotherapy and/or radiotherapy; consent to participate in the research through signing the informed consent form

Exclusion criteria

Exclusion criteria: Patients receiving systemic medication for the treatment and prevention of mucositis; patients unable to comply with the treatment procedure or with the oral hygiene protocol

Design outcomes

Primary

Measure	Time frame
It is expected that a reduction in the severity of oral mucositis, as assessed by the World Health Organization scale, will be observed, associated with a reduction in the number of colony-forming units per milliliter of yeast species of the genus Candida and other microorganisms of dental interest, through the regression of lesions and control of the microbial load, after the application of therapies during the seven, fourteen, twenty-one, and thirty-day clinical follow-up periods	—

Measure

Time frame

It is expected that a reduction in the severity of oral mucositis, as assessed by the World Health Organization scale, will be observed, associated with a reduction in the number of colony-forming units per milliliter of yeast species of the genus Candida and other microorganisms of dental interest, through the regression of lesions and control of the microbial load, after the application of therapies during the seven, fourteen, twenty-one, and thirty-day clinical follow-up periods

—

Secondary

Measure	Time frame
The study expects to find a reduction in patient-reported pain, measured using a visual analog scale, and an increase in salivary flow for the treatment of xerostomia, in addition to identifying, through molecular methods, the yeast species originating from the patients for future correlation with the response to treatments	—

Countries

Contacts

Public ContactFrancine Rosa

Universidade Federal da Bahia

drfransilva@yahoo.com.br+55(77)981031135

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: May 1, 2026